Respiratory System Diagnosis with Ventilator Support ≤96h DRG Reimbursement

Summary & Overview

Respiratory System Diagnosis with Ventilator Support <=96 Hours: Inpatient Reimbursement Overview

DRG 208 encompasses respiratory system diagnoses with mechanical ventilator support for less than or equal to ninety-six hours, including acute respiratory failure and related pulmonary conditions that require short-term ventilatory assistance. It matters for inpatient reimbursement because ventilator use increases resource intensity and influences how Centers for Medicare & Medicaid Services assigns payment under the Diagnosis-Related Group system.

Respiratory System Diagnosis with Ventilator Support <=96 HoursDRG Respiratory System Diagnosis with Ventilator Support <=96 HoursDRG 208Diagnosis-Related GroupInpatient ReimbursementMedicarePulmonologyCritical CareMechanical Ventilation

DRG 208 Overview

DRG 208 covers inpatient cases involving respiratory system diagnoses that require mechanical ventilator support for less than or equal to ninety-six hours. This category includes acute respiratory failure, respiratory infections, and other pulmonary conditions necessitating short-term ventilatory assistance. It is important for Medicare payment because ventilator use and respiratory diagnosis drive higher resource intensity and influence hospital reimbursement under the inpatient payment system. Proper classification into this Diagnosis-Related Group affects payment relative to other respiratory and ventilator-related groups.

National Payment Rates

Payer-negotiated rates for DRG 208 span from as low as $370 to as high as $90K across the payers shown, with mean values ranging roughly from $24K to $45K. The widest spread is between the lowest observed value ($370) and the highest ($90K). See the table and chart below for payer-specific percentiles and distributions.

Mean Rates by Payer — National — DRG 208

The CMS 2023 data reflect national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($24.1k), average submitted covered charges ($125.0k), average Medicare payment amount ($21.0k), and total discharges (30.1k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates in Alaska for DRG 208 range from $31K to $66K across the major payers, with Anthem and Blue Cross Blue Shield clustered at the lower end and Cigna showing higher average and much wider spread. The Cigna benchmark includes a notable maximum of $110K, a clear deviation above national medians for this DRG. Reference the table and chart below for payer-level details and distribution.

Key Insights for Alaska

Anthem is the highest paying payer in Alaska at $43K, while Blue Cross Blue Shield is the lowest at $31K.
Cigna shows substantial variability in Alaska with a mean of $66K and a max of $110K, representing a meaningful upside versus national medians for this DRG.

Clinical Trials

Acute ventilatory management trials: randomized or protocolized studies comparing ventilator strategies (such as low tidal volume protocols, weaning bundles, or specific modes of mechanical ventilation) initiated in the ICU for patients with respiratory diagnoses requiring intubation and ventilator support <=96 hours. These studies enroll adults with acute respiratory failure from causes like COPD exacerbation, pneumonia, pulmonary edema, or respiratory distress syndromes who are expected to have short-duration ventilation, and they measure time to successful extubation, incidence of ventilator-associated complications, and ICU length of stay. This research directly informs clinicians on best practices to shorten ventilator duration and reduce complications, and it helps payers anticipate resource utilization and costs associated with short-term mechanical ventilation under DRG 208.
Comparative effectiveness and bundle-of-care studies during early critical care: pragmatic trials or observational comparative-effectiveness research evaluating multi-component early care bundles (including sedation protocols, spontaneous breathing trials, early mobilization, dysphagia screening, and infection prevention measures) for patients admitted with respiratory diagnoses who require brief ventilator support. The populations studied are heterogeneous respiratory DRG patients whose ventilation is expected to resolve within 96 hours; outcomes include ventilator-free days, ICU/hospital LOS, readmission rates, and rates of hospital-acquired infection. Findings are relevant to hospital systems and payers because effective bundles can reduce short-term ICU resource use, lower complication rates and readmissions, and influence DRG-level cost-effectiveness and quality metrics.
Post-discharge functional and utilization outcomes research: cohort studies and interventions focused on post-acute outcomes for patients discharged after an ICU stay with brief ventilator support, assessing functional recovery, pulmonary rehabilitation needs, subsequent healthcare utilization (ED visits, readmissions), and long-term respiratory symptoms. These studies target survivors of short-duration invasive ventilation across respiratory diagnoses and aim to identify risk factors for poor recovery and cost drivers in the 30–90 day post-discharge window. Understanding these downstream outcomes is important to providers for planning discharge services and follow-up, and to payers for predicting post-acute costs and designing value-based care pathways relevant to DRG 208.

Related Codes

164-MAJOR-CHEST-PROCEDURES-WITH-CC

Major Chest Procedures with CC: Inpatient Reimbursement Overview

207-RESPIRATORY-SYSTEM-DIAGNOSIS-WITH-VENTILATOR-SUPPORT-96-HOURS

Respiratory System Diagnosis with Ventilator Support >96 Hours: Inpatient Reimbursement Overview

163-MAJOR-CHEST-PROCEDURES-WITH-MCC

Major Chest Procedures with MCC: Inpatient Reimbursement Overview

204-RESPIRATORY-SIGNS-AND-SYMPTOMS

Respiratory Signs and Symptoms: Inpatient Reimbursement Overview

173-ULTRASOUND-ACCELERATED-AND-OTHER-THROMBOLYSIS-WITH-PRINCIPAL-DIAGNOSIS-PULMONARY-EMBOLISM

Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism: Inpatient Reimbursement Overview

182-RESPIRATORY-NEOPLASMS-WITHOUT-CC-MCC

Respiratory Neoplasms without CC/MCC: Inpatient Reimbursement Overview

201-PNEUMOTHORAX-WITHOUT-CC-MCC

Pneumothorax without CC/MCC: Inpatient Reimbursement Overview

196-INTERSTITIAL-LUNG-DISEASE-WITH-MCC

Interstitial Lung Disease with MCC: Inpatient Reimbursement Overview

190-CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-WITH-MCC

Chronic Obstructive Pulmonary Disease with MCC: Inpatient Reimbursement Overview

167-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-CC

Other Respiratory System O.R. Procedures with CC: Inpatient Reimbursement Overview

Showing 1–10 of 40

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$24K	$130K	$21K	30K

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Mean Rates by Payer — Alaska — DRG 208

Key Insights for Alaska

Anthem is the highest paying payer in Alaska at $43K, while Blue Cross Blue Shield is the lowest at $31K.
Cigna shows substantial variability in Alaska with a mean of $66K and a max of $110K, representing a meaningful upside versus national medians for this DRG.

Clinical Trials

Acute ventilatory management trials: randomized or protocolized studies comparing ventilator strategies (such as low tidal volume protocols, weaning bundles, or specific modes of mechanical ventilation) initiated in the ICU for patients with respiratory diagnoses requiring intubation and ventilator support <=96 hours. These studies enroll adults with acute respiratory failure from causes like COPD exacerbation, pneumonia, pulmonary edema, or respiratory distress syndromes who are expected to have short-duration ventilation, and they measure time to successful extubation, incidence of ventilator-associated complications, and ICU length of stay. This research directly informs clinicians on best practices to shorten ventilator duration and reduce complications, and it helps payers anticipate resource utilization and costs associated with short-term mechanical ventilation under DRG 208.
Comparative effectiveness and bundle-of-care studies during early critical care: pragmatic trials or observational comparative-effectiveness research evaluating multi-component early care bundles (including sedation protocols, spontaneous breathing trials, early mobilization, dysphagia screening, and infection prevention measures) for patients admitted with respiratory diagnoses who require brief ventilator support. The populations studied are heterogeneous respiratory DRG patients whose ventilation is expected to resolve within 96 hours; outcomes include ventilator-free days, ICU/hospital LOS, readmission rates, and rates of hospital-acquired infection. Findings are relevant to hospital systems and payers because effective bundles can reduce short-term ICU resource use, lower complication rates and readmissions, and influence DRG-level cost-effectiveness and quality metrics.
Post-discharge functional and utilization outcomes research: cohort studies and interventions focused on post-acute outcomes for patients discharged after an ICU stay with brief ventilator support, assessing functional recovery, pulmonary rehabilitation needs, subsequent healthcare utilization (ED visits, readmissions), and long-term respiratory symptoms. These studies target survivors of short-duration invasive ventilation across respiratory diagnoses and aim to identify risk factors for poor recovery and cost drivers in the 30–90 day post-discharge window. Understanding these downstream outcomes is important to providers for planning discharge services and follow-up, and to payers for predicting post-acute costs and designing value-based care pathways relevant to DRG 208.